Asymmetric Synthesis of Tetrahydrobenzofurans and Annulated Dihydropyrans via Cooperative One-Pot Organo- and Silver-Catalysis

Uğur Kaya; Pankaj Chauhan; Kristina Deckers; Rakesh Puttreddy; Kari Rissanen; Gerhard Raabe; Dieter Enders

doi:10.1055/s-0035-1561468

Synthesis, Table of Contents

Synthesis 2016; 48(19): 3207-3216
DOI: 10.1055/s-0035-1561468

paper

Georg Thieme Verlag Stuttgart · New York

Asymmetric Synthesis of Tetrahydrobenzofurans and Annulated Dihydropyrans via Cooperative One-Pot Organo- and Silver-Catalysis

Authors

Uğur Kaya

^aInstitute of Organic Chemistry, RWTH Aachen University, Landoltweg 1, 52074 Aachen, Germany Email: enders@rwth-aachen.de
Pankaj Chauhan

^aInstitute of Organic Chemistry, RWTH Aachen University, Landoltweg 1, 52074 Aachen, Germany Email: enders@rwth-aachen.de
Kristina Deckers

^aInstitute of Organic Chemistry, RWTH Aachen University, Landoltweg 1, 52074 Aachen, Germany Email: enders@rwth-aachen.de
Rakesh Puttreddy

^bDepartment of Chemistry, Nanoscience Center, University of Jyvaskyla, 40014 JYU, Finland
Kari Rissanen

^bDepartment of Chemistry, Nanoscience Center, University of Jyvaskyla, 40014 JYU, Finland
Gerhard Raabe

^aInstitute of Organic Chemistry, RWTH Aachen University, Landoltweg 1, 52074 Aachen, Germany Email: enders@rwth-aachen.de
Dieter Enders*

^aInstitute of Organic Chemistry, RWTH Aachen University, Landoltweg 1, 52074 Aachen, Germany Email: enders@rwth-aachen.de

Abstract

Full Text

PDF Download All articles of this category

In memory of Professor Jean Normant

Key words

asymmetric synthesis - organocatalysis - one-pot synthesis - silver catalysis - annulation

Benzofuran and its partially hydrogenated analogues are important heterocyclic building blocks and very common structures in natural products with interesting biological and pharmaceutical properties. This is also true for structurally isomeric annulated dihydropyrans.[1] Natural products such as the furanomonoterpene evodone (I), which has been isolated from Evodia hortensis, exhibits significant inhibitory activity on the seed germination of certain species.[2] Curzerenone (II) and bisabolangelone (III) are other natural products with antibacterial and anti-inflammatory activities,[3] [4] respectively, whereas the diterpenoid maoecrystal V (IV) is a potent selective HeLa cell inhibitor.[5] The dihydropyran-type natural product crolibulin (V) and the pharmaceutical HA14-1 (VI) show anticancer properties (Figure [1]).[6]

Figure 1 Bioactive natural products and pharmaceuticals containing the partially hydrogenated benzofuran and dihydropyran moieties

Recently, much effort has been invested in the synthesis of tetrahydrobenzofuran and dihydropyran core structures.[7] Singh and co-workers developed a silver-catalyzed interrupted Feist–Bénary reaction between ynones and β-diketones to provide dihydrofurans in moderate to good yields and good to excellent enantioselectivities (Scheme [1]).[8] Feng and co-workers reported an asymmetric domino Michael addition/O-alkylation reaction between cyclohexane-1,3-dione derivatives and bromonitrostyrenes catalyzed by a bifunctional N,N′-dioxide organocatalyst to afford polysubstituted bicyclic dihydrofurans.[9] Calter’s group published another interesting synthesis of highly substituted furanoids via an organocatalytic asymmetric aldol/oxa-Michael addition sequence between 2-ene-1,4-diketones and dimedone in the presence of a bis(cinchona alkaloid)-pyrimidine catalyst.[10] The Schneider group developed an interesting enantioselective phosphoric acid-catalyzed synthesis of 4-aryl-4H-chromenes via a conjugate addition of 1,3-diketones to in situ generated ortho-quinone methides followed by a cyclodehydration reaction.[11]

Scheme 1 Approaches for the asymmetric synthesis of tetrahydrobenzofurans and annulated dihydropyran derivatives

The activation of alkynes for subsequent transformations has become an important tool in organic chemistry to develop new and valuable reactions. Alkyne functionalization can be achieved in two crucial routes: σ-activation (σ-bond metathesis or σ-coordination) and π-activation (π-complex formation).[12] The coinage metals (Cu, Ag and Au) are suitable candidates for alkyne functionalization due to their good alkynophilicity.[13] Especially, silver(I) salts have emerged as powerful activators of alkynes. The advantages of stability, nontoxicity, low price, or catalyst compatibility with organocatalysts favor the choice of silver in C≡C bond activation reactions such as alkynylation, cycloaddition, cycloisomerization, or hydrofunctionalization.[14]

Merging organocatalysis and metal catalysis enables multiple unique transformations in one-pot and this catalytic approach has become a powerful strategy in asymmetric synthesis. Particularly cooperative, relay, synergistic, and dual catalysis variations, where all reactants and catalysts are present from the beginning, is challenging and require high compatibility of the combined catalysts.[15]

In search of new methods for acquiring valuable bioactive heterocyclic compounds and our interest in the combination of organocatalysts and silver(I) salts,[16] we investigated an asymmetric Michael addition/hydroalkoxylation sequence between 1,3-diketones and alkyne-tethered nitroalkenes catalyzed by a bifunctional squaramide[17] and a silver(I) salt to provide the desired tetrahydrobenzofurans. We began our investigation by choosing dimedone (1) and nitroalkene 2a as model substrates. To our delight, the one-pot reaction of 1 and 2a in CH₂Cl₂ at room temperature catalyzed by squaramide A and Ag₂O afforded the desired 5-exo-dig cyclization product 3a in 98% yield and 94% enantiomeric excess (Scheme [2]). Inspired by these excellent results, the reaction was carried out with different squaramide and thiourea catalysts A–I along with Ag₂O as silver(I) salt. All squaramide catalysts as well as thiourea catalysts provided the tetrahydrobenzofuran in high yields and moderate to very good enantioselectivities. The best result was obtained with squaramide A, which gave 98% yield and 94% ee.

Scheme 2 Catalyst screening for the Michael addition/hydroalkoxylation reaction of 1 with 2a

The reaction conditions were optimized further by varying the solvent (Table [1]). The solvent screening indicated that the chlorinated solvents and Et₂O gave very good results. The best yields were obtained with CH₂Cl₂ and CHCl₃. We chose CH₂Cl₂ over CHCl₃ on the basis of its lower toxicity. Further optimization studies were carried out by screening transition metal catalysts for the hydroalkoxylation reaction. Ag₂CO₃ provided the annulated product with 99% yield and 95% ee. The cost aspect led to our decision to use Ag₂O instead of Ag₂CO₃. After carrying out the reaction at different temperatures and catalyst loadings of the squaramide and the silver(I) salt, we determined the optimal reaction conditions, these being 0.5 mol% of the squaramide A, 1 mol% of Ag₂O, and CH₂Cl₂ as solvent at room temperature.

Table 1 Further Optimization Studies^a

Entry	M-catalyst	Solvent	Yield (%)^b	ee (%)^c
1	Ag₂O	toluene	90	92
2	Ag₂O	Et₂O	99	92
3	Ag₂O	CHCl₃	99	95
4	Ag₂O	DCE	99	94
5	Ag₂O	CH₂Cl₂	99	95
6	PtCl₂	CH₂Cl₂	traces	–
7	CuCl	CH₂Cl₂	37	94
8	AgOTf	CH₂Cl₂	25	22
9	AgBF₄	CH₂Cl₂	20	47
10	Ag₂CO₃	CH₂Cl₂	99	95
11	AuClPPh₃	CH₂Cl₂	n.d.	–
12^d	Ag₂O	CH₂Cl₂	99	96
13^e	Ag₂O	CH₂Cl₂	99	95
14^f	Ag₂O	CH₂Cl₂	99	96
15^g	Ag₂O	CH₂Cl₂	99	97

^a Reaction conditions: Dimedone (1; 0.25 mmol), nitroalkene 2a (1.1 equiv), cat. A (1 mol%), Ag₂O (10 mol%), solvent (2.5 mL, 0.1 M).

^b Yield of 3a after flash chromatography.

^c The enantiomeric excess was determined by HPLC on a chiral stationary phase.

^d The reaction was carried out with A (0.5 mol%).

^e The reaction was carried out with Ag₂O (5 mol%) and A (0.5 mol%).

^f The reaction was carried out with Ag₂O (1 mol%) and A (0.5 mol%).

^g The reaction was carried out with Ag₂O (1 mol%) and A (0.5 mol%) at 0 °C.

The substrate scope of the cooperative organo- and silver-catalyzed asymmetric one-pot reaction was then explored for the reaction of dimedone (1) with various alkyne-tethered nitroalkenes 2 under optimal reaction conditions (Table [2]). The nitroalkenes with electron-withdrawing and electron–donating groups worked smoothly under the cooperative catalysis condition to provide tetrahydrobenzofurans 3b–f in excellent yields and very good enantioselectivities. The sterically encumbered 1-naphthyl- and 2-naphthyl-substituted nitroalkenes led to the formation of the desired tetrahydrobenzofurans 3g,h in very good yields and excellent enantiomeric excesses (Table [2]). Furthermore, the one-pot Michael addition/hydroalkoxylation sequence with heteroaryl-substituted nitroalkenes provided the desired annulated product 3i in excellent yields and enantioselectivity.

Table 2 Substrate Scope^a

3	R	Yield (%)^b	ee (%)^c
a	Ph	99	96
b	3-MeOC₆H₄	98	96
c	2-ClC₆H₄	97	95
d	4-F₃CC₆H₄	93	94
e	3-MeC₆H₄	97	95
f	3,4-(OCH₂O)C₆H₃	97	95
g	2-naphthyl	94	97
h	1-naphthyl	90	95
i	2-furanyl	96	96

^a Reaction conditions: Dimedone (1; 0.25 mmol), nitroalkene 2 (1.1 equiv), cat. A (0.5 mol%), Ag₂O (1 mol%), solvent (2.5 mL, 0.1 M).

^b Yield of 3a after flash chromatography.

^c The enantiomeric excess was determined by HPLC on a chiral stationary phase.

An extended substrate scope was investigated using different cyclic 1,3-diketones based on five- and six-membered rings. The reaction with 1,3-cyclohexanedione led to the tetrahydrobenzofuran product in good yield and excellent enantioselectivity (Scheme [3, 5a]) Interestingly, a dihydropyran derivative 5b could be obtained in moderate yield and good enantiomeric excess using 1,3-cyclopentanedione. The substrate scope of the cooperative catalytic reaction was extended further to 1,3-diketones bearing heteroatoms, which also provided dihydropyran derivatives in moderate to very good yields and high enantioselectivities (Scheme [3, 5c, d]).

Scheme 3 Extended substrate scope to annulated dihydropyrans

The developed one-pot asymmetric transformation was also conducted with various 5-substituted 1,3-cyclohexanediones to introduce another stereocenter via desymmetrization. The desired tetrahydrobenzofurans could be obtained in very good yields and enantioselectivities, but the diastereomeric ratio was virtually 1:1 in all attempts (Scheme [4, 7a–d]).

Scheme 4 Extended substrate scope

To evaluate the efficiency and synthetic utility of the current Michael addition/hydroalkoxylation strategy, tetrahydrobenzofuran 3a was prepared on a gram-scale maintaining the excellent yield and ee value (Scheme [5]).

Scheme 5 Gram-scale synthesis of 3a

The absolute configuration of the tetrahydrobenzofurans was determined by X-ray crystal structure analysis of compound 5a (Figure [2])[18] in combination with a CD measurement and calculation (Figure [3]).

Figure 2 X-ray crystal structure of tetrahydrobenzofuran 5a

Figure 3 Measured (red) CD spectrum of 5a. The black curve is the calculated CD spectrum of 5a with the S-configuration at carbon atom C3. Δε in 1000 cm²mol^–1 and λ in nm. For details, see the Supporting Information.

The absolute configuration of the dihydropyran derivatives is based on an X-ray crystallographic analysis of compound 5d (Figure [4]).[18]

Figure 4 X-ray crystal structure of dihydropyran derivative 5d

This one-pot Michael addition/hydroalkoxylation protocol is proposed to proceed via two catalytic cycles (Scheme [6]). The first organocatalytic cycle involves the synergistic activation of the 1,3-diketone 1 and the nitroalkene 2 by the bifunctional squaramide A, where the squaramide moiety activates the nitroalkene 2 through the formation of hydrogen bonds to the nitro group and simultaneously the 1,3-diketone undergoes activation by the tertiary amine to promote the Michael addition from the Re-face. In the second catalytic cycle the silver forms a π-complex for the electrophilic activation of the internal alkyne to facilitate a 5-exo-dig or a 6-endo-dig annulation reaction leading to the vinylsilver intermediate. The latter undergoes a fast protodeargentation to provide the desired product 3, 5 and 7.

Scheme 6 Proposed mechanism of the one-pot Michael addition/ hydroalkoxylation reaction

In conclusion, we have developed a one-pot asymmetric Michael addition/hydroalkoxylation protocol by merging a bifunctional squaramide and a silver(I) salt at a very low catalyst loading. The combination of both catalytic systems enabled the formation of the desired tetrahydrobenzofurans and annulated dihydropyranes in moderate to excellent yields and good to excellent enantiomeric excesses.

Unless otherwise noted, all commercially available chemicals were used without purification. All solvents were distilled and purified according to standard procedures. Analytical TLC was performed using SIL G-25 UV₂₅₂ from Macherey & Nagel (particle size 0.040–0.063 nm; 230–240 mesh. flash) and visualized with ultraviolet radiation at 254 nm. ¹H, ¹³C, and ¹⁹F NMR spectra were recorded at ambient temperature on a Varian Innova 400 or Innova 600 spectrometer. Chemical shifts for ¹H NMR and ¹³C NMR spectra are reported in parts per million (ppm) and coupling constants in hertz (Hz). Standard abbreviations are used for the spin multiplicity (qi = quintet). Optical rotations were measured on a PerkinElmer 241 polarimeter. Melting points were measured on a LLG MPM-H2 melting point instrument. Mass spectra were acquired on a Finnigan SSQ7000 (EI, 70 eV) spectrometer and on a ThermoFinnigan LCQ Deca XP plus (ESI) spectrometer and high-resolution ESI spectra on a ThermoFisher Scientific LTQ Orbitrap XL. Analytical HPLC was performed on a Aligent 1100, Aligent 1260, or Hewlett-Packard 1100 Series instrument using chiral stationary phases (Daicel Chiralpak IC, Daicel Chiralpak IA, Daicel Chiralpak AD, Daicel Chiralpak AS, Daicel Chiralpak IB columns). Analytical SFC was performed on a THAR-SFC MethodStation II with a WATERS 2998 Photodiode Array Detector using chiral stationary phases (Daicel Chiralcel OJ-H). Catalyst A and B,[19] D–I [20] and the nitroalkenes 2 [16c] were prepared according to known procedures.

Tetrahydrobenzofurans and Annulated Dihydropyrans; General Procedure

A mixture of 1,3-diketones 1,4, or 6 (0.25 mmol), nitroalkene 2 (0.275 mmol, 1.1 equiv), catalyst A (0.5 mol%), and Ag₂O (1 mol%) in CH₂Cl₂ (2.5 mL, 0.1 M) was stirred at r.t. until the intermediate Michael adduct was completely converted as indicated by TLC. The crude product was directly subjected to flash chromatography on silica (n-pentane/Et₂O or n-pentane/CH₂Cl₂) to afford the corresponding product 3, 5, or 7.

(R)-(Z)-2-Benzylidene-6,6-dimethyl-3-(nitromethyl)-3,5,6,7-tetrahydrobenzofuran-4(2H)-one (3a)

Compound 3a was isolated after flash chromatography (n-pentane/Et₂O, 1:1); yield: 75 mg (96%); colorless solid; mp 136–138 °C; R_f = 0.22 (n-pentane/Et₂O, 1:1); [α]_D ²⁴ +96.6 (c = 0.6, MeOH).

HPLC: Daicel Chiralpak IC, n-heptane/i-PrOH (7:3), 1.0 mL/min, λ = 254 nm, t _R (minor) = 7.6 min, t _R (major) = 6.4 min; 96% ee.

IR (ATR): 2955, 2330, 2086, 1900, 1645, 1546, 1492, 1397, 1335, 1286, 1219, 1174, 1140, 1092, 998, 917, 849, 755, 694 cm^–1.

¹H NMR (600 MHz, C₆D₆): δ = 7.52 (d, J = 7.4 Hz, 2 H, ArH), 7.19 (t, J = 7.8 Hz, 2 H, ArH), 7.04 (t, J = 7.4 Hz, 1 H, ArH), 5.42 (d, J = 2.0 Hz, 1 H, OC=CH), 4.36 (dd, J = 13.1, 6.3 Hz, 1 H, CHHNO₂), 4.17 (dd, J = 13.1, 4.7 Hz, 1 H, CHHNO₂), 3.92 (s, 1 H, CHCH₂), 1.93 (d, J = 16.0 Hz, 1 H, CH₂), 1.85 (d, J = 16.0 Hz, 1 H, CH₂), 1.66 (d, J = 17.9 Hz, 1 H, CH₂), 1.58 (d, J = 17.9 Hz, 1 H, CH₂), 0.64 (s, 3 H, CH₃), 0.58 (s, 3 H, CH₃).

¹³C NMR (151 MHz, C₆D₆): δ = 191.6 (C=O), 173.4 (C_q), 153.4 (C_q), 133.9 (C_q), 128.7 (2 C, ArC), 128.3 (2 C, ArC), 127.0 (ArC), 111.1 (C_q), 106.0 (OC=CH), 75.3 (CH₂NO₂), 50.5 (CH₂), 41.9 (CHCH₂), 36.1 (CH₂), 33.2 [C(CH₃)₂], 28.4 (CH₃), 27.2 (CH₃).

MS (EI, 70 eV): m/z (%) = 313.1 (1, [M]⁺), 267.1 (17, [M – NO₂]⁺), 253.0 (7, [M – CH₂NO₂]⁺), 90.1 (38, [CH₂C₆H₅]⁺), 77.1 (27, [C₆H₅]⁺).

HRMS (ESI⁺): m/z [M + Na]⁺ calcd for C₁₈H₁₉NO₄Na: 336.1206; found: 336.1195.

(R)-(Z)-2-(3-Methoxybenzylidene)-6,6-dimethyl-3-(nitromethyl)-3,5,6,7-tetrahydrobenzofuran-4(2H)-one (3b)

Compound 3b was isolated after flash chromatography (n-pentane/Et₂O, 2:1); yield: 84 mg (98%); colorless solid; mp 127–129 °C; R_f = 0.17 (n-pentane/Et₂O, 1:1); [α]_D ²⁴ +67.7 (c = 0.4, benzene).

HPLC: Daicel Chiralpak IC, n-heptane/i-PrOH (7:3), 0.7 mL/min, λ = 254 nm, t _R (minor) = 14.0 min, t _R (major) = 15.4 min; 96% ee.

IR (ATR): 2934, 2293, 2090, 1891, 1649, 1566, 1399, 1232, 1015, 840, 692 cm^–1.

¹H NMR (600 MHz, CDCl₃): δ = 7.25 (m, 1 H, ArH), 7.11 (m, 2 H, ArH), 6.83–6.78 (m, 1 H, ArH), 5.71 (d, J = 2.2 Hz, 1 H, OC=CH), 4.89 (dd, J = 13.3, 3.9 Hz, 1 H, CHHNO₂), 4.73 (dd, J = 13.3, 7.1 Hz, 1 H, CHHNO₂), 4.58–4.53 (m, 1 H, CHCH₂), 3.82 (s, 3 H, OCH₃), 2.54 (m, 2 H, CH₂), 2.31 (m, 2 H, CH₂), 1.17 (s, 3 H, CH₃), 1.16 (s, 3 H, CH₃).

¹³C NMR (151 MHz, CDCl₃): δ = 193.6 (C=O), 175.0 (C_q), 159.6 (C_q), 153.3 (C_q), 134.5 (C_q), 129.4 (ArC), 121.3 (ArC), 114.2 (ArC), 112.8 (ArC), 111.3 (C_q), 106.7 (OC=CH), 75.7 (CH₂NO₂), 55.2 (OCH₃), 51.0 (CH₂), 41.7 (CHCH₂), 37.2 (CH₂), 34.4 [C(CH₃)₂], 29.0 (CH₃), 28.3 (CH₃).

MS (EI, 70 eV): m/z (%) = 343.3 (5, [M]⁺), 297.3 (34, [M – NO₂]⁺), 283.3 (12, [M – CH₂NO₂]⁺).

HRMS (ESI⁺): m/z [M + Na]⁺ calcd for C₁₉H₂₁NO₅Na: 366.1312; found: 366.1310.

(R)-(Z)-2-(2-Chlorobenzylidene)-6,6-dimethyl-3-(nitromethyl)-3,5,6,7-tetrahydrobenzofuran-4(2H)-one (3c)

Compound 3c was isolated after flash chromatography (n-pentane/Et₂O, 1:1); yield: 84 mg (97%); colorless solid; mp 130–132 °C; R_f = 0.36 (n-pentane/Et₂O, 1:1); [α]_D ²⁴= 115.8 (c = 0.5, benzene).

HPLC: Daicel Chiralpak IA, n-heptane/i-PrOH (7:3), 0.7 mL/min, λ = 230 nm, t _R (minor) = 8.4 min, t _R (major) = 9.0 min; 95% ee.

IR (ATR): 2956, 2314, 2084, 1648, 1552, 1396, 1284, 1214, 1017, 972, 852, 754, 692 cm^–1.

¹H NMR (600 MHz, C₆D₆): δ = 7.95 (dd, J = 7.9, 1.6 Hz, 1 H, ArH), 7.17 (dd, J = 8.1, 1.2 Hz, 1 H, ArH), 6.97 (m, 1 H, ArH), 6.73 (m, 1 H, ArH), 6.04 (d, J = 2.3 Hz, 1 H, OC=CH), 4.48 (dd, J = 13.2, 5.3 Hz, 1 H, CHHNO₂), 3.99 (dd, J = 13.2, 3.6 Hz, 1 H, CHHNO₂), 3.69 (s, 1 H, CHCH₂), 1.92 (d, J = 16.0 Hz, 1 H, CH₂), 1.83 (d, J = 16.0 Hz, 1 H, CH₂), 1.67 (d, J = 17.9 Hz, 1 H, CH₂), 1.57 (d, J = 17.9 Hz, 1 H, CH₂), 0.64 (s, 3 H, CH₃), 0.56 (s, 3 H, CH₃).

¹³C NMR (151 MHz, C₆D₆): δ = 191.6 (C=O), 173.2 (C_q), 155.4 (C_q), 132.7 (C_q), 131.9 (C_q), 130.2 (ArC), 129.4 (ArC), 128.1 (ArC), 126.5 (ArC), 111.4 (C_q), 101.5 (OC=CH), 75.2 (CH₂NO₂), 50.5 (CH₂), 42.0 (CHCH₂), 36.1 (CH₂), 33.2 [C(CH₃)₂], 28.4 (CH₃), 27.2 (CH₃).

MS (EI, 70 eV): m/z (%) = 348.3 (1, [M + H]⁺), 303.3 (7, [M – NO₂, ³⁷Cl]⁺), 301.2 (37, [M – NO₂, ³⁵Cl]⁺), 289.2 (2, [M – CH₂NO₂, ³⁷Cl]⁺), 287.2 (6, [M – NO₂, ³⁵Cl]⁺).

HRMS (ESI⁺): m/z [M + Na]⁺ calcd for C₁₈H₁₈ClNO₄Na: 370.0812; found: 370.0813.

(R)-(Z)-6,6-Dimethyl-3-(nitromethyl)-2-[4-(trifluoromethyl)benzylidene]-3,5,6,7-tetrahydrobenzofuran-4(2H)-one (3d)

Compound 3d was isolated after flash chromatography (n-pentane/Et₂O, 1:2); yield: 106 mg (93%); colorless solid; mp 54–56 °C; R_f = 0.14 (n-pentane/Et₂O, 1:1); [α]_D ²⁴ +49.2 (c = 0.3, benzene).

HPLC: Daicel Chiralpak IC, n-heptane/i-PrOH (8:2), 1.0 mL/min, λ = 254 nm, t _R (minor) = 7.9 min, t _R (major) = 6.1 min; 94% ee.

IR (ATR): 2962, 1949, 1692, 1651, 1615, 1552, 1400, 1321, 1219, 1166, 1116, 1067, 1014, 917, 862, 834, 791, 758, 703 cm^–1.

¹H NMR (400 MHz, CDCl₃): δ = 7.59 (m, 4 H, ArH), 5.76 (d, J = 2.2 Hz, 1 H, OC=CH), 4.90 (dd, J = 13.4, 3.9 Hz, 1 H, CHHNO₂), 4.75 (dd, J = 13.4, 6.9 Hz, 1 H, CHHNO₂), 4.55 (m, 1 H, CHCH₂), 2.55 (m, 2 H, CH₂), 2.31 (s, 2 H, CH₂), 1.17 (s, 3 H, CH₃), 1.16 (s, 3 H, CH₃).

¹³C NMR (101 MHz, CDCl₃): δ = 193.5 (C=O), 174.7 (C_q), 155.0 (C_q), 136.8 (C_q), 128.7 (3 C, ArC), 125.3 (2 C, ArC), 122.7 (CF₃), 111.4 (C_q), 105.4 (OC=CH), 75.4 (CH₂NO₂), 51.0 (CH₂), 41.9 (CHCH₂), 37.2 (CH₂), 34.4 [C(CH₃)₂], 28.9 (CH₃), 28.2 (CH₃).

¹⁹F NMR (376 MHz, CDCl₃): δ = –62.61 (s).

MS (EI, 70 eV): m/z (%) = 382.3 (3, [M + H]⁺), 335.3 (29, [M – NO₂]⁺), 321.2 (9, [M – CH₂NO₂]⁺).

HRMS (ESI⁺): m/z [M + Na]⁺ calcd for C₁₉H₁₈F₃NO₄Na: 404.1080; found: 404.1069.

(R)-(Z)-6,6-Dimethyl-2-(3-methylbenzylidene)-3-(nitromethyl)-3,5,6,7-tetrahydrobenzofuran-4(2H)-one (3e)

Compound 3e was isolated after flash chromatography (n-pentane/Et₂O, 1:1); yield: 79 mg (97%); colorless solid; mp 138–140 °C; R_f = 0.26 (n-pentane/Et₂O, 1:1); [α]_D ²⁴ +71.2 (c = 0.4, benzene).

HPLC: Daicel Chiralpak IB, n-heptane/i-PrOH (7:3), 0.7 mL/min, λ = 254 nm, t _R (minor) = 11.0 min, t _R (major) = 10.0 min; 95% ee.

IR (ATR): 2957, 2290, 2086, 1644, 1547, 1474, 1403, 1328, 1280, 1214, 1171, 1093, 1006, 891, 840, 781, 697 cm^–1.

¹H NMR (600 MHz, CDCl₃): δ = 7.37 (d, J = 7.8 Hz, 1 H, ArH), 7.32 (s, 1 H, ArH), 7.23 (t, J = 7.7 Hz, 1 H, ArH), 7.06 (d, J = 7.5 Hz, 1 H, ArH), 5.70 (d, J = 2.2 Hz, 1 H, OC=CH), 4.89 (dd, J = 13.2, 3.9 Hz, 1 H, CHHNO₂), 4.73 (dd, J = 13.3, 7.1 Hz, 1 H, CHHNO₂), 4.55 (m, 1 H, CHCH₂), 2.55 (m, 2 H, CH₂), 2.35 (s, 3 H, CH₃), 2.32 (m, 2 H, CH₂), 1.17 (s, 3 H, CH₃), 1.16 (s, 3 H, CH₃).

¹³C NMR (151 MHz, CDCl₃): δ = 193.6 (C=O), 175.1 (C_q), 152.8 (C_q), 138.0 (C_q), 133.2 (C_q), 129.4 (ArC), 128.4 (ArC), 128.2 (ArC), 125.7 (ArC), 111.3 (C_q), 106.9 (OC=CH), 75.7 (CH₂NO₂), 51.0 (CH₂), 41.7 (CHCH₂), 37.3 (CH₂), 34.4 [C(CH₃)₂], 29.0 (CH₃), 28.3 (CH₃), 21.5 (ArCH₃).

MS (EI, 70 eV): m/z (%) = 327.2 (2, [M]⁺), 328.2 (9, [M + H]⁺), 281.3 (26, [M – NO₂]⁺), 267.3 (17, [M – CH₂NO₂]⁺).

HRMS (ESI⁺): m/z [M + Na]⁺ calcd for C₁₉H₂₁NO₄Na: 350.1363; found: 350.1356.

(R)-(Z)-2-(Benzo[d][1,3]dioxol-5-ylmethylene)-6,6-dimethyl-3-(nitromethyl)-3,5,6,7-tetrahydrobenzofuran-4(2H)-one (3f)

Compound 3f was isolated after flash chromatography (n-pentane/Et₂O, 1:2); yield: 87 mg (97%); colorless solid; mp 138–140 °C; R_f = 0.21 (n-pentane/Et₂O, 1:1); [α]_D ²⁴ +72.8 (c = 0.4, benzene).

HPLC: Daicel Chiralpak IB, n-heptane/EtOH (7:3), 1.0 mL/min, λ = 254 nm, t _R (minor) = 9.8 min, t _R (major) = 13.8 min; 95% ee.

IR (ATR): 2960, 1650, 1549, 1493, 1398, 1292, 1239, 1097, 1027, 928, 875, 804, 697 cm^–1.

¹H NMR (600 MHz, C₆D₆): δ = 7.42 (m, 1 H, ArH), 6.72 (m, 1 H, ArH), 6.64 (m, 1 H, ArH), 5.36 (d, J = 2.1 Hz, 1 H, OC=CH), 5.27 (m, 2 H, OCH₂O), 4.31 (dd, J = 12.9, 6.4 Hz, 1 H, CHHNO₂), 4.18 (dd, J = 13.0, 3.8 Hz, 1 H, CHHNO₂), 3.94 (s, 1 H, CHCH₂), 1.92 (d, J = 16.0 Hz, 1 H, CH₂), 1.84 (d, J = 16.0 Hz, 1 H, CH₂), 1.56 (d, J = 17.9 Hz, 1 H, CH₂), 1.48 (d, J = 17.9 Hz, 1 H, CH₂), 0.63 (s, 3 H, CH₃), 0.57 (s, 3 H, CH₃).

¹³C NMR (151 MHz, C₆D₆): δ = 191.7 (C=O), 173.4 (C_q), 151.9 (C_q), 148.1 (C_q), 146.8 (C_q), 128.1 (C_q), 123.1 (ArC), 111.0 (C_q), 108.6 (ArC), 108.2 (ArC), 106.0 (OC=CH), 100.8 (OCH₂O), 75.4 (CH₂NO₂), 50.5 (CH₂), 41.8 (CHCH₂), 36.0 (CH₂), 33.1 [C(CH₃)₂], 28.3 (CH₃), 27.2 (CH₃).

MS (EI, 70 eV): m/z (%) = 358.3 (5, [M + H]⁺), 357.3 (17, [M]⁺), 311.3 (24, [M – NO₂]⁺), 297.3 (28, [M – CH₂NO₂]⁺).

HRMS (ESI⁺): m/z [M + Na]⁺ calcd for C₁₉H₁₉NO₆Na: 380.1105; found: 380.1094.

(R)-(Z)-6,6-Dimethyl-2-(naphthalen-2-ylmethylene)-3-(nitromethyl)-3,5,6,7-tetrahydrobenzofuran-4(2H)-one (3g)

Compound 3g was isolated after flash chromatography (n-pentane/Et₂O, 1:1 to 1:2); yield: 85 mg (94%); colorless solid; mp 133–135 °C; R_f = 0.24 (n-pentane/Et₂O, 1:1); [α]_D ²⁴ +93.9 (c = 0.4, benzene).

HPLC: Daicel Chiralpak IA, n-heptane/i-PrOH (7:3), 0.7 mL/min, λ = 254 nm, t _R (minor) = 11.1 min, t _R (major) = 11.7 min; 97% ee.

IR (ATR): 2956, 2313, 2073, 2002, 1646, 1549, 1463, 1401, 1290, 1218, 1173, 1140, 1090, 1019, 900, 862, 821, 749, 699 cm^–1.

¹H NMR (600 MHz, CDCl₃): δ = 7.94 (s, 1 H, ArH), 7.84–7.77 (m, 3 H, ArH), 7.72 (dd, J = 8.6, 1.7 Hz, 1 H, ArH), 7.50–7.43 (m, 2 H, ArH), 5.90 (d, J = 2.1 Hz, 1 H, OC=CH), 4.94 (dd, J = 13.3, 3.9 Hz, 1 H, CHHNO₂), 4.77 (dd, J = 13.3, 7.2 Hz, 1 H, CHHNO₂), 4.62 (m, 1 H, CHCH₂), 2.60 (m, 2 H, CH₂), 2.34 (s, 2 H, CH₂), 1.19 (s, 3 H, CH₃), 1.18 (s, 3 H, CH₃).

¹³C NMR (151 MHz, CDCl₃): δ = 193.6 (C=O), 175.0 (C_q), 153.3 (C_q), 133.4 (C_q), 132.4 (C_q), 130.9 (C_q), 128.1 (ArC), 128.0 (ArC), 127.8 (ArC), 127.6 (ArC), 126.5 (ArC), 126.3 (ArC), 126.1 (ArC), 111.4 (C_q), 106.9 (OC=CH), 75.7 (CH₂NO₂), 51.1 (CH₂), 41.8 (CHCH₂), 37.3 (CH₂), 34.4 [C(CH₃)₂], 29.0 (CH₃), 28.3 (CH₃).

MS (EI, 70 eV): m/z (%) = 364.3 (2, [M + H]⁺), 363.3 (4, [M]⁺), 317.3 (27, [M – NO₂]⁺), 303.3 (12, [M – CH₂NO₂]⁺).

HRMS (ESI⁺): m/z [M + Na]⁺ calcd for C₂₂H₂₁NO₄Na: 386.1363; found: 386.1351.

(R)-(Z)-6,6-Dimethyl-2-(naphthalen-1-ylmethylene)-3-(nitromethyl)-3,5,6,7-tetrahydrobenzofuran-4(2H)-one (3h)

Compound 3h was isolated after flash chromatography (n-pentane/Et₂O, 1:1); yield: 82 mg (90%); colorless solid; mp 165–167 °C; R_f = 0.23 (n-pentane/Et₂O, 1:1); [α]_D ²⁴ +110.1 (c = 0.4, benzene).

HPLC: Daicel Chiralpak IB, n-heptane/EtOH (7:3), 0.5 mL/min, λ = 230 nm, t _R (minor) = 15.9 min, t _R (major) = 16.9 min; 95% ee.

IR (ATR): 3056, 2959, 1648, 1550, 1398, 1294, 1218, 1172, 1141, 1089, 1019, 975, 915, 838, 780, 699 cm^–1.

¹H NMR (600 MHz, CDCl₃): δ = 7.98 (d, J = 8.3 Hz, 1 H, ArH), 7.87–7.77 (m, 3 H, ArH), 7.56–7.46 (m, 3 H, ArH), 6.41 (d, J = 2.1 Hz, 1 H, OC=CH), 5.02 (dd, J = 13.1, 3.9 Hz, 1 H, CHHNO₂), 4.83 (dd, J = 13.1, 7.2 Hz, 1 H, CHHNO₂), 4.72–4.66 (m, 1 H, CHCH₂), 2.48 (m, 2 H, CH₂), 2.32 (m, 2 H, CH₂), 1.16 (s, 3 H, CH₃), 1.15 (s, 3 H, CH₃).

¹³C NMR (151 MHz, CDCl₃): δ = 193.6 (C=O), 175.2 (C_q), 154.2 (C_q), 133.6 (C_q), 131.1 (C_q), 129.4 (C_q), 128.6 (ArC), 128.1 (ArC), 127.1 (ArC), 126.4 (ArC), 125.9 (ArC), 125.3 (ArC), 123.8 (ArC), 111.5 (C_q), 103.5 (OC=CH), 76.0 (CH₂NO₂), 51.0 (CH₂), 41.7 (CHCH₂), 37.2 (CH₂), 34.4 [C(CH₃)₂], 29.0 (CH₃), 28.3 (CH₃).

MS (EI, 70 eV): m/z (%) = 364.4 (2, [M + H]⁺), 363.3 (7, [M]⁺), 317.3 (24, [M – NO₂]⁺), 303.3 (6, [M – CH₂NO₂]⁺).

HRMS (ESI⁺): m/z [M + Na]⁺ calcd for C₂₂H₂₁NO₄Na: 386.1323; found: 386.1345.

(R)-(Z)-2-(Furan-2-ylmethylene)-6,6-dimethyl-3-(nitromethyl)-3,5,6,7-tetrahydrobenzofuran-4(2H)-one (3i)

Compound 3i was isolated after flash chromatography (n-pentane/Et₂O, 1:1); yield: 73 mg (96%); colorless solid; mp 103–105 °C; R_f = 0.31 (n-pentane/Et₂O, 1:1); [α]_D ²⁴ +85.7 (c = 0.4, benzene).

HPLC: Daicel Chiralpak IB, n-heptane/EtOH (7:3), 0.7 mL/min, λ = 254 nm, t _R (minor) = 9.3 min, t _R (major) = 10.3 min; 96% ee.

IR (ATR): 2960, 2876, 2081, 1988, 1649, 1554, 1466, 1374, 1292, 1228, 1167, 1089, 1049, 1016, 989, 920, 884, 816, 747, 700, 671 cm^–1.

¹H NMR (600 MHz, C₆D₆): δ = 7.05 (d, J = 1.6 Hz, 1 H, OCH), 6.59 (d, J = 3.3 Hz, 1 H, CH), 6.19 (dd, J = 3.3, 1.8 Hz, 1 H, CH), 5.61 (d, J = 2.3 Hz, 1 H, OC=CH), 4.29 (dd, J = 13.2, 6.1 Hz, 1 H, CHHNO₂), 4.04 (dd, J = 13.2, 3.7 Hz, 1 H, CHHNO₂), 3.79 (s, 1 H, CHCH₂), 1.90 (d, J = 16.0 Hz, 1 H, CH₂), 1.82 (d, J = 16.0 Hz, 1 H, CH₂), 1.71 (d, J = 17.8 Hz, 1 H, CH₂), 1.63 (d, J = 17.8 Hz, 1 H, CH₂), 0.62 (s, 3 H, CH₃), 0.57 (s, 3 H, CH₃).

¹³C NMR (151 MHz, C₆D₆): δ = 191.6 (C=O), 173.2 (C_q), 152.1 (C_q), 149.1 (C_q), 141.2 (OCH), 111.6 (CH), 111.3 (C_q), 109.5 (CH), 96.2 (OC=CH), 74.8 (CH₂NO₂), 50.5 (CH₂), 41.4 (CHCH₂), 36.2 (CH₂), 33.2 [C(CH₃)₂], 28.3 (CH₃), 27.2 (CH₃).

MS (EI, 70 eV): m/z (%) = 304.1 (1, [M + H]⁺), 303.1 (5, [M]⁺), 257.1 (24, [M – NO₂]⁺), 243.0 (13, [M – CH₂NO₂]⁺).

HRMS (ESI⁺): m/z [M + Na]⁺ calcd for C₁₆H₁₇NO₅Na: 326.0999; found: 326.0990.

(R)-(Z)-2-Benzylidene-3-(nitromethyl)-3,5,6,7-tetrahydrobenzofuran-4(2H)-one (5a)

Compound 5a was isolated after flash chromatography (n-pentane/Et₂O, 1:2); yield: 56 mg (79%); colorless solid; mp 117–119 °C; R_f = 0.14 (n-pentane/Et₂O, 1:1); [α]_D ²⁴ +74.9 (c = 0.5, benzene).

HPLC: Daicel Chiralpak AS, n-heptane/EtOH (7:3), 0.7 mL/min, λ = 254 nm, t _R (minor) = 13.3 min, t _R (major) = 15.9 min; 98% ee.

IR (ATR): 2953, 2322, 2087, 1892, 1641, 1547, 1384, 1217, 1176, 1051, 974, 841, 696 cm^–1.

¹H NMR (600 MHz, CDCl₃): δ = 7.54 (d, J = 7.4 Hz, 2 H, ArH), 7.34 (t, J = 7.8 Hz, 2 H, ArH), 7.24 (t, J = 7.4 Hz, 1 H, ArH), 5.73 (d, J = 2.1 Hz, 1 H, OC=CH), 4.92 (dd, J = 13.2, 3.8 Hz, 1 H, CHHNO₂), 4.67 (dd, J = 13.2, 7.6 Hz, 1 H, CHHNO₂), 4.58 (m, 1 H, CHCH₂), 2.72–2.65 (m, 2 H, CH₂), 2.47–2.42 (m, 2 H, CH₂), 2.16 (qi, J = 6.4 Hz, 2 H, CH₂).

¹³C NMR (151 MHz, CDCl₃): δ = 194.1 (C=O), 176.0 (C_q), 152.8 (C_q), 133.3 (C_q), 128.7 (ArC), 128.5 (ArC), 127.3 (ArC), 112.7 (C_q), 106.8 (OC=CH), 75.9 (CH₂NO₂), 41.7 (CHCH₂), 36.6 (CH₂), 23.4 (CH₂), 21.5 (CH₂).

MS (EI, 70 eV): m/z (%) = 286.3 (13, [M + H]⁺), 285.2 (2, [M]⁺), 239.3 (21, [M – NO₂]⁺), 225.2 (19, [M – CH₂NO₂]⁺).

HRMS (ESI⁺): m/z [M + Na]⁺ calcd for C₁₆H₁₅NO₄Na: 308.0893; found: 308.0893.

(R)-4-(Nitromethyl)-2-phenyl-6,7-dihydrocyclopenta[b]pyran-5(4H)-one (5b)

Compound 5b was isolated after flash chromatography (n-pentane/Et₂O, 1:2); yield: 43 mg (63%); colorless solid; mp 153–155 °C; R_f = 0.19 (n-pentane/Et₂O, 1:1); [α]_D ²⁴ –162.9 (c = 0.4, benzene).

HPLC: Daicel Chiralpak IC, n-heptane/EtOH (7:3), 0.7 mL/min, λ = 230 nm, t _R (minor) = 10.7 min, t _R (major) = 8.8 min; 94% ee.

IR (ATR): 3075, 2922, 2308, 2096, 1902, 1665, 1543, 1393, 1234, 991, 856, 764, 696 cm^–1.

¹H NMR (600 MHz, C₆D₆): δ = 7.32 (m, 2 H, ArH), 7.04 (m, 3 H, ArH), 5.09 (d, J = 3.6 Hz, 1 H, OC=CH), 4.20 (m, 2 H, CH₂NO₂), 3.47 (m, 1 H, CHCH₂), 1.89 (ddd, J = 17.8, 7.4, 2.8 Hz, 1 H, CH), 1.81 (ddd, J = 17.9, 7.4, 2.5 Hz, 1 H, CH), 1.75 (m, 1 H, CH), 1.68 (m, 1 H, CH).

¹³C NMR (151 MHz, C₆D₆): δ = 200.7 (C=O), 179.2 (C_q), 150.7 (C_q), 132.3 (C_q), 129.2 (ArC), 128.4 (2 C, ArC), 124.9 (2 C, ArC), 111.8 (C_q), 98.7 (OC=CH), 76.6 (CH₂NO₂), 32.8 (CH₂), 29.8 (CHCH₂), 24.9 (CH₂).

MS (EI, 70 eV): m/z (%) = 272.2 (3, [M + H]⁺), 225.2 (27, [M – NO₂]⁺), 211.2 (84, [M – CH₂NO₂]⁺).

HRMS (ESI⁺): m/z [M + Na]⁺ calcd for C₁₅H₁₃NO₄Na: 294.0737; found: 294.0732.

(R)-4-(Nitromethyl)-2-phenyl-4,8-dihydropyrano[3,4-b]pyran-5(6H)-one (5c)

Compound 5c was isolated after flash chromatography (n-pentane/Et₂O, 1:1 to 1:2); yield: 22 mg (31%); colorless solid; mp 113–115 °C; R_f = 0.43 (n-pentane/Et₂O, 1:1); [α]_D ²⁴ –213.5 (c = 0.4, benzene).

HPLC: Daicel Chiralpak IA, n-heptane/i-PrOH (7:3), 0.7 mL/min, λ = 254 nm, t _R (minor) = 14.2 min, t _R (major) = 11.9 min; 90% ee.

IR (ATR): 2962, 1675, 1635, 1546, 1494, 1439, 1393, 1270, 1229, 1139, 1056, 994, 952, 873, 814, 764, 677 cm^–1.

¹H NMR (600 MHz, C₆D₆): δ = 7.22–7.19 (m, 2 H, ArH), 7.05–7.02 (m, 3 H, ArH), 5.10 (d, J = 4.3 Hz, 1 H, OC=CH), 4.06 (dd, J = 11.7, 7.0 Hz, 1 H, CHHNO₂), 4.01 (dd, J = 11.7, 3.8 Hz, 1 H, CHHNO₂), 3.92 (d, J = 15.9 Hz, 1 H, CH₂), 3.75 (d, J = 16.2 Hz, 1 H, CH₂), 3.67–3.63 (m, 1 H, CHCH₂), 3.59 (dd, J = 15.9, 1.7 Hz, 1 H, CH₂), 3.52 (dd, J = 16.1, 1.4 Hz, 1 H, CH₂).

¹³C NMR (151 MHz, C₆D₆): δ = 192.1 (C=O), 165.3 (C_q), 149.2 (C_q), 131.9 (C_q), 129.2 (ArC), 128.3 (ArC), 124.6 (ArC), 106.1 (C_q), 99.1 (OC=CH), 77.6 (CH₂NO₂), 71.1 (CH₂), 63.5 (CH₂), 28.4 (CHCH₂).

MS (EI, 70 eV): m/z (%) = 241.1 (17, [M – NO₂]⁺), 227.1 (45, [M – CH₂NO₂]⁺).

HRMS (ESI⁺): m/z [M + Na]⁺ calcd for C₁₅H₁₃NO₅Na: 310.0686; found: 310.0686.

(R)-1,3-Dimethyl-5-(nitromethyl)-7-phenyl-1,5-dihydro-2H-pyrano[2,3-d]pyrimidine-2,4(3H)-dione (5d)

Compound 5d was isolated after flash chromatography [n-pentane/CH₂Cl₂ (1:4) to pure CH₂Cl₂]; yield: 77 mg (94%); bright yellow solid; mp 224–226 °C; R_f = 0.26 (CH₂Cl₂/Et₂O, 20:1); [α]_D ²⁴ –144.5 (c = 0.4, CHCl₃).

HPLC: Daicel Chiralpak AS, n-heptane/EtOH (7:3), 1.0 mL/min, λ = 254 nm, t _R (minor) = 10.3 min, t _R (major) = 7.5 min; 88% ee.

IR (ATR): 2954, 2324, 2107, 1645, 1476, 1375, 1203, 1003, 753, 690 cm^–1.

¹H NMR (600 MHz, CDCl₃): δ = 7.58–7.52 (m, 2 H, ArH), 7.45–7.41 (m, 3 H, ArH), 5.71 (d, J = 4.4 Hz, 1 H, OC=CH), 4.83–4.74 (m, 2 H, CH₂NO₂), 4.24 (dt, J = 6.1, 4.3 Hz, 1 H, CHCH₂), 3.54 (s, 3 H, CH₃), 3.39 (s, 3 H, CH₃).

¹³C NMR (151 MHz, CDCl₃): δ = 162.0 (C=O), 154.3 (C=O), 150.5 (C_q), 149.7 (C_q), 131.2 (C_q), 130.0 (ArC), 128.8 (2 C, ArC), 124.8 (2 C, ArC), 99.2 (OC=CH), 84.0 (C_q), 77.9 (CH₂NO₂), 30.9 (CHCH₂), 29.2 (CH₃), 28.2 (CH₃).

MS (EI, 70 eV) m/z (%) = 283.1 (20, [M – NO₂]⁺), 269.0 (71, [M – CH₂NO₂]⁺).

HRMS (ESI⁺): m/z [M + Na]⁺ calcd for C₁₆H₁₅N₃O₅Na: 352.0904; found: 352.0894.

(R)-(Z)-2-Benzylidene-6-methyl-3-(nitromethyl)-3,5,6,7-tetrahydrobenzofuran-4(2H)-one (7a)

Compound 7a was isolated after flash chromatography (n-pentane/Et₂O, 1:1 to 1:2); yield: 73 mg (98%); colorless solid; mp 175–177 °C; R_f = 0.24 (n-pentane/Et₂O, 1:1); [α]_D ²⁴ +85.5 (c = 0.5, MeOH).

HPLC: Daicel Chiralpak IC, n-heptane/i-PrOH (7:3), 0.5 mL/min, λ = 254 nm, t _R (minor) 1 = 27.5 min, t _R (major) 1 = 16.6 min; t _R (minor) 2 = 29.9 min, t _R (major) 2 = 18.2 min; 94% ee, dr = 1:1.

IR (ATR): 2951, 2925, 2871, 2153, 2086, 2048, 1989, 1735, 1691, 1650, 1549, 1389, 1288, 1205, 1163, 1099, 1016, 973, 914, 873, 847, 811, 752, 694 cm^–1.

¹H NMR (600 MHz, C₆D₆): δ = 7.51 (m, 4 H, ArH, ArH_Diast.), 7.18 (m, 4 H, Ar-H, ArH_Diast.), 7.03 (m, 2 H, ArH, ArH_Diast.), 5.44 (d, J = 2.2 Hz, 1 H, OC=CH), 5.42 (d, J = 2.2 Hz, 1 H, OC=CH_Diast.), 4.34 (dd, J = 13.1, 6.4 Hz, 1 H, CH₂NO₂), 4.28 (dd, J = 13.0, 6.6 Hz, 1 H, CH₂NO_{2 Diast.}), 4.22 (ddd, J = 13.0, 7.9, 3.8 Hz, 2 H, CH₂NO₂, CH₂NO_{2 Diast.}), 3.94 (m, 2 H, CHCH₂, CHCH_{2 Diast.}), 2.07 (m, 4 H, CH₂, CH_{2 Diast.}), 1.65 (m, 4 H, CH₂, CH_{2 Diast.}), 1.56 (m, 2 H, CHCH₃, CHCH_{3 Diast.}), 1.44 (m, 1 H, CHH), 1.27 (m, 1 H, CHH _Diast.), 0.50 (d, J = 6.6 Hz, 3 H, CH₃), 0.46 (d, J = 6.3 Hz, 3 H, CH_{3 Diast.}).

¹³C NMR (151 MHz, C₆D₆): δ = 191.8 (C=O), 191.8 (C=O_Diast.), 174.2 (C_q), 174.0 (C_{q Diast.}), 153.3 (C_q), 153.3 (C_{q Diast.}), 133.9 (C_q), 133.9 (C_{q Diast.}), 128.7 (4 C, ArC, ArC_Diast.), 128.4 (4 C, ArC, ArC_Diast.), 127.0 (2 C, ArC, ArC_Diast.), 112.1 (C_q), 111.9 (C_{q Diast.}), 106.1 (OC=CH), 106.0 (OC=CH_Diast.), 75.7 (CH₂NO₂), 75.1 (CH₂NO_{2 Diast.}), 44.6 (CH₂), 44.5 (CH_{2 Diast.}), 41.9 (CHCH₂), 41.8 (CHCH_{2 Diast.}), 30.3 (CH₂), 30.2 (CH_{2 Diast.}), 29.2 (CHCH₃), 29.0 (CHCH_{3 Diast.}), 20.1 (CH₃), 12.0 (CH_{3 Diast.}).

MS (EI, 70 eV): m/z (%) = 300.0 (3, [M + H]⁺), 253.1 (19, [M – NO₂]⁺), 239.0 (11, [M – CH₂NO₂]⁺).

HRMS (ESI⁺): m/z [M + Na]⁺ calcd for C₁₇H₁₇NO₄Na: 322.1050; found: 322.1049.

(R)-(Z)-2-Benzylidene-6-isopropyl-3-(nitromethyl)-3,5,6,7-tetrahydrobenzofuran-4(2H)-one (7b)

Compound 7b was isolated after flash chromatography (n-pentane/Et₂O, 1:1 to 1:2); yield: 67 mg (82%); colorless solid; mp 141–143 °C; R_f = 0.33 (n-pentane/Et₂O, 1:1); [α]_D ²⁴ +52.7 (c = 0.5, benzene).

HPLC: Daicel Chiralpak IA, n-heptane/EtOH (97:3), 1.0 mL/min, λ = 254 nm, t _R (minor) 1 = 41.7 min, t _R (major) 1 = 63.8 min; t _R (minor) 2 = 50.4 min, t _R (major) 2 = 58.3 min; 93% ee, dr = 1:1.

IR (ATR): 3352, 2956, 2325, 2096, 1649, 1546, 1381, 1100, 958, 842, 756, 687 cm^–1.

¹H NMR (600 MHz, C₆D₆): δ = 7.53 (m, 4 H, ArH, ArH _Diast.), 7.20 (m, 4 H, ArH, ArH_Diast.), 7.05 (m, 2 H, ArH, ArH_Diast.), 5.49 (d, J = 2.1 Hz, 1 H, OC=CH), 5.47 (d, J = 2.1 Hz, 1 H, OC=CH_Diast.), 4.35 (m, 1 H, CHHNO₂), 4.30 (m, 3 H, CH₂NO₂, CH₂NO_{2 Diast.}), 4.05 (m, 1 H, CHCH₂), 4.01 (m, 1 H, CHCH_{2 Diast.}), 2.17 (m, 2 H, CHH, CHH_Diast.), 1.79 (m, 3 H, CHH, CHH_Diast.), 1.59 [m, 2 H, CHCH(CH₃)₂, CHCH(CH₃)_{2 Diast.}], 1.43 (m, 2 H, CHH, CHH _Diast.), 1.31 (m, 1 H, CHH), 1.01 [m, 2 H, CH(CH₃)₂, CH(CH₃)_{2 Diast.}], 0.48 [m, 12 H, CH(CH ₃)₂, CH(CH ₃)_{2 Diast.}].

¹³C NMR (151 MHz, C₆D₆): δ = 192.1 (C=O), 192.1 (C=O _Diast.), 174.7 (C_q), 174.7 (C_{q Diast.}), 153.4 (C_q), 153.4 (C_{q Diast.}), 133.9 (C_q), 133.9 (C_{q Diast.}), 128.7 (4 C, ArC, ArC_Diast.), 128.4 (4 C, ArC, ArC_Diast.), 127.1 (2 C, ArC, ArC _Diast.), 112.2 (C_q), 112.0 (C_{q Diast.}), 106.1 (OC=CH), 106.0 (OC=CH_Diast.), 75.8 (CH₂NO₂), 75.1 (CH₂NO_{2 Diast.}), 41.9 (CHCH₂), 41.9 (CHCH_{2 Diast.}), 40.7 (CH₂), 40.4 (CH_{2 Diast.}), 40.3 [CHCH(CH₃)₂], 40.2 [CHCH(CH₃)_{2 Diast.}], 31.4 [CH(CH₃)₂], 31.3 [CH(CH₃)_{2 Diast.}], 26.1 (CH₂), 25.9 (CH_{2 Diast.}), 19.3 (CH₃), 19.1 (CH_{3 Diast.}), 18.8 (CH₃), 18.7 (CH_{3 Diast.}).

MS (EI⁺, 70 eV): m/z (%) = 328.1 (3, [M + H]⁺), 327.1 (1, [M]⁺), 281.1 (33, [M – NO₂]⁺), 267.1 (8, [M – CH₂NO₂]⁺).

HRMS (ESI⁺): m/z [M + Na]⁺ calcd for C₁₉H₂₁NO₄Na: 350.1363; found: 350.1362.

(R)-(Z)-2-Benzylidene-3-(nitromethyl)-6-phenyl-3,5,6,7-tetrahydrobenzofuran-4(2H)-one (7c)

Compound 7c was isolated after flash chromatography (n-pentane/Et₂O, 1:1 to 1:2); yield: 85 mg (94%); colorless solid; mp 128–130 °C; R_f = 0.24 (n-pentane/Et₂O, 1:1); [α]_D ²⁴ +64.8 (c = 0.5, benzene).

HPLC: Daicel Chiralpak AD, n-heptane/EtOH (1:1), 1.0 mL/min, λ = 254 nm, t _R (minor) 1 = 9.2 min, t _R (major) 1 = 17.1 min; t _R (minor) 2 = 11.0 min, t _R (major) 2 = 13.9 min; 94% ee, dr = 1:1.

IR (ATR): 3027, 2305, 2102, 1910, 1735, 1647, 1546, 1397, 1204, 1002, 909, 853, 753, 694 cm^–1.

¹H NMR (600 MHz, C₆D₆): δ = 7.51 (m, 4 H, ArH, ArH_Diast.), 7.19 (m, 4 H, ArH, ArH_Diast.), 7.04 (m, 8 H, ArH, _Diast.), 6.72 (m, 4 H, ArH, ArH_Diast.), 5.48 (s, 2 H, OC=CH, OC=CH_Diast.), 4.32 (m, 4 H, CH₂NO₂, CH₂NO_{2 Diast.}), 4.06 (m, 1 H, CHCH₂), 4.00 (m, 1 H, CHCH_{2 Diast.}), 2.83 (m, 1 H, CHC₆H₅), 2.70 (m, 1 H, CHC₆H_{5 Diast.}), 2.36 (m, 2 H, CH_{2 Diast.}), 2.23 (dd, J = 16.2, 12.5 Hz, 1 H, CHH), 2.11 (dd, J = 16.2, 12.9 Hz, 1 H, CHH), 1.92 (m, 4 H, CH₂, CH_{2 Diast.}).

¹³C NMR (151 MHz, C₆D₆): δ = 191.0 (C=O), 190.9 (C=O_Diast.), 173.8 (C_q), 173.8 (C_{q Diast.}), 153.3 (C_q), 153.2 (C_{q Diast.}), 142.0 (C_q), 142.0 (C_{q Diast.}), 133.8 (C_q), 133.8 (C_{q Diast.}), 128.7 (4 C, ArC, ArC_Diast.), 128.5 (4 C, ArC, ArC_Diast.), 128.4 (4 C, ArC, ArC_Diast.), 127.1 (2 C, ArC, ArC_Diast.), 127.0 (2 C, ArC, ArC_Diast.), 126.6 (4 C, ArC, ArC_Diast.) 112.3 (C_q), 112.2 (C_{q Diast.}), 106.3 (OC=CH), 106.3 (OC=CH_Diast.), 75.7 (CH₂NO₂), 75.0 (CH₂NO_{2 Diast.}), 43.7 (CH₂), 43.6 (CH_{2 Diast.}), 41.9 (CHCH₂), 41.8 (CHCH_{2 Diast.}), 39.7 (CHPh), 39.6 (CHPh_Diast.), 30.1 (CH₂), 30.0 (CH_{2 Diast.}).

MS (EI⁺, 70 eV): m/z (%) = 361.1 (1, [M + H]⁺), 315.1 (38, [M – NO₂]⁺), 301.1 (7, [M – CH₂NO₂]⁺).

HRMS (ESI⁺): m/z [M + Na]⁺ calcd for C₂₂H₁₉NO₄Na: 384.1206; found: 384.1207.

(R)-(Z)-2-Benzylidene-6-(furan-2-yl)-3-(nitromethyl)-3,5,6,7-tetrahydrobenzofuran-4(2H)-one (7d)

Compound 7d was isolated after flash chromatography (n-pentane/Et₂O, 1:1); yield: 86 mg (98%); colorless solid; mp 143–145 °C; R_f = 0.21 (n-pentane/Et₂O, 1:1); [α]_D ²⁴ +64.8 (c = 0.4, MeOH).

SFC: Daicel Chiralcel OJ-H, CO₂/MeCN (8:2), 4.0 mL/min, λ = 222 nm, t _R (minor) 1 = 3.9 min, t _R (major) 1 = 5.2 min; t _R (minor) 2 = 7.1 min, t _R (major) 2 = 9.7 min; 99% ee, dr = 1:1.

IR (ATR): 2914, 2327, 2098, 1647, 1547, 1393, 1201, 1009, 849, 752 cm^–1.

¹H NMR (600 MHz, C₆D₆): δ = 7.47 (t, J = 6.9 Hz, 4 H, ArH, ArH_Diast.), 7.17 (m, 4 H, ArH, ArH_Diast.), 7.03 (m, 2 H, ArH, ArH_Diast.), 6.96–6.93 (m, 2 H, OCH, OCH_Diast.), 5.97 (ddd, J = 6.6, 3.2, 1.9 Hz, 2 H, ArH, ArH_Diast.), 5.65 (d, J = 3.2 Hz, 2 H, ArH, ArH_Diast.), 5.44 (d, J = 2.2 Hz, 1 H, OC=CH), 5.41 (d, J = 2.2 Hz, 1 H, OC=CH_Diast.), 4.25 (m, 2 H, CHHNO₂, CHHNO_{2 Diast.}), 4.17 (m, 2 H, CHHNO₂, CHHNO_{2 Diast.}), 4.01 (m, 1 H, CHCH₂), 3.89 (m, 1 H, CHCH_{2 Diast.}), 2.88 (m, 1 H, CHAr), 2.82 (m, 1 H, CHAr_Diast.), 2.37 (m, 2 H, CH₂, CH_{2 Diast.}), 2.21 (m, 2 H, CH₂, CH_{2 Diast.}), 2.07 (m, 4 H, CH₂, CH_{2 Diast.}).

¹³C NMR (151 MHz, C₆D₆): δ = 190.2 (2 C, C=O, C=O_Diast.), 172.9 (C_q), 172.8 (C_{q Diast.}), 155.1 (C_q), 155.0 (C_{q Diast.}), 153.1 (C_q), 153.0 (C_{q Diast.}), 141.4 (2 C, OCH_furanyl, OCH_{furanyl, Diast.}), 133.7 (C_q), 133.7 (C_{q Diast.}), 128.7 (4 C, ArC, ArC_Diast.), 128.3 (4 C, ArC, ArC_Diast.), 127.1 (2 C, ArC, ArC_Diast.), 112.3 (C_q), 112.2 (C_{q Diast.}), 110.1 (CH_furanyl), 110.1 (CH_{furanyl, Diast.}), 106.3 (OC=CH), 106.3 (OC=CO _Diast.), 104.9 (CH_furanyl), 104.8 (CH_{furanyl, Diast.}), 75.4 (CH₂NO₂), 75.0 (CH₂NO_{2 Diast.}), 41.8 (CHCH₂), 41.7 (CHCH_{2 Diast.}), 40.8 (CH₂), 40.7 (CH_{2 Diast.}), 33.0 (CH_furanyl), 32.8 (CH_{furanyl, Diast.}), 27.4 (2 C, CH₂, CH_{2 Diast.}).

MS (EI, 70 eV): m/z (%) = 351.1 (1, [M]⁺), 305.1 (44, [M – NO₂]⁺), 291.1 (7, [M – CH₂NO₂]⁺).

HRMS (ESI⁺): m/z [M + Na]⁺ calcd for C₂₀H₁₇NO₅Na: 374.0999; found: 374.0997.

References

References

1a Sainsbury M. In Heterocyclic Chemistry . Abel EW. The Royal Society of Chemistry; Cambridge: 2001: 58
1b Wolfe JP. Hay MB. Tetrahedron 2007; 63: 261
1c Miyabe H. Miyata O. Naito T. In Heterocycles in Natural Product Synthesis . Majumdar KC. Chattopadhyay SK. Wiley-VCH; Weinheim: 2011: 153
1d Lorente A. Lamariano-Merketegi J. Albericio F. Álvarez M. Chem. Rev. 2013; 113: 4567
1e Dar AM. Shamsuzzaman Eur. Chem. Bull. 2015; 4: 249
1f Kumar KA. Renuka N. Kumar GV. Lokeshwari DM. J. Chem. Pharm. Res. 2015; 7: 693

2a Juo R.-R. Herz W. J. Org. Chem. 1985; 50: 700
2b Srikrishna A. Krishnan K. Tetrahedron Lett. 1988; 29: 4995
2c Tanrisever N. Fischer NH. Williamson GB. Phytochemistry 1988; 27: 2523
2d Aso M. Qjida A. Yang G. Cha O.-J. Osawa E. Kanematsu K. J. Org. Chem. 1993; 58: 3960
2e Lee YR. Lee GJ. Kang KY. Bull. Korean Chem. Soc. 2002; 23: 1477

3 Joshi SC. Mathela CS. Pharmacog. Res. 2012; 4: 80
4 Jung HW. Mahesh R. Park JH. Boo YC. Park KM. Park Y.-K. Int. Immunopharmacol. 2010; 10: 155

5a Gong J. Lin G. Sun W. Li C.-C. Yang Z. J. Am. Chem. Soc. 2010; 132: 16745
5b Lu P. Mailyan A. Gu Z. Guptill DM. Wang H. Davies HM. L. Zakarian A. J. Am. Chem. Soc. 2014; 136: 17738
5c Zheng C. Dubovyk I. Lazarski KE. Thomson RJ. J. Am. Chem. Soc. 2014; 136: 17750
5d Zhang W.-B. Lin G. Shao W.-B. Gong J.-X. Yang Z. Chem. Asian J. 2015; 10: 903
5e Zhang W.-B. Shao W.-B. Li F.-Z. Gong J.-X. Yang Z. Chem. Asian J. 2015; 10: 1874

6a Adili A. Tao Z.-L. Chen D.-F. Han Z.-Y. Org. Biomol. Chem. 2015; 13: 2247
6b Wu B. Gao X. Yan Z. Huang W.-X. Zhou Y.-G. Tetrahedron Lett. 2015; 56: 4334

7a Barange DK. Raju BR. Kavala V. Kuo C.-W. Tu Y.-C. Yao C.-F. Tetrahedron 2010; 66: 3754
7b Han Y. Hou H. Yao R. Fu Q. Yan C.-G. Synthesis 2010; 4061
7c Rueping M. Parra A. Uria U. Besselièvre F. Merino E. Org. Lett. 2010; 12: 5680
7d Devi RB. Henrot M. De Paolis M. Maddaluno J. Org. Biomol. Chem. 2011; 9: 6509
7e Dong L. Deng L. Lim YH. Leung GY. C. Chen DY.-K. Chem. Eur. J. 2011; 17: 5778
7f Wu M.-Y. Wang M.-Q. Li K. Feng X.-W. He T. Wang N. Yu W.-Q. Tetrahedron Lett. 2011; 52: 679
7g Chawla R. Singh AK. Yadav LD. S. Tetrahedron Lett. 2012; 53: 3382
7h Jonek A. Berger S. Haak E. Chem. Eur. J. 2012; 18: 15504
7i Liu Z. Fan G.-P. Wang G.-W. Chem. Commun. 2012; 48: 11665
7j Kalpogiannaki D. Martini C.-I. Nikopoulou A. Nyxas JA. Pantazi V. Hadjiarapoglou LP. Tetrahedron 2013; 69: 1566
7k Xia L. Lee YR. Adv. Synth. Catal. 2013; 355: 1261
7l Yao C. Wang Y. Li T. Yu C. Li L. Wang C. Tetrahedron 2013; 69: 10593
7m Kasare S. Bankar SK. Ramasastry SS. V. Org. Lett. 2014; 16: 4284
7n Bosnidou A.-E. Kalpogiannaki D. Karanestora S. Nixas JA. Hadjiarapoglou LP. J. Org. Chem. 2015; 80: 1279
7o Riveira MJ. Quiroga GN. Mata EG. Gandon V. Mischne MP. J. Org. Chem. 2015; 80: 6515
7p Wang S. He L.-Y. Guo L.-N. Synthesis 2015; 47: 3191
7q Wei J. Nie B.-J. Peng R. Cheng X.-H. Wang S. He P. Synlett 2016; 27: 626
7r Kale A. Chennapuram M. Bingi C. Nanubolu JB. Atmakur K. Org. Biomol. Chem. 2016; 14: 582
7s Liu W. Lai X. Zha G. Xu Y. Sun P. Xia T. Shen Y. Org. Biomol. Chem. 2016; 14: 3603

8 Sinha D. Biswas A. Singh VK. Org. Lett. 2015; 17: 3302
9 Feng J. Lin L. Yu K. Liu X. Feng X. Adv. Synth. Catal. 2015; 357: 1305
10 Calter MA. Korotkov A. Org. Lett. 2015; 17: 1385
11 El-Sepelgy O. Haseloff S. Alamsetti SK. Schneider C. Angew. Chem. Int. Ed. 2014; 53: 7923
12 Kumar RK. Bi X. Chem. Commun. 2016; 52: 853

13a Zhang L. Fang G. Kumar RK. Bi X. Synthesis 2015; 47: 2317
13b Zi W. Toste D. Chem. Soc. Rev. 2016; 45
13c Yoshida H. ACS Catal. 2016; 6: 1799

14a Naodovic M. Yamamoto H. Chem. Rev. 2008; 108: 3132
14b Yamamoto Y. Chem. Rev. 2008; 108: 3199
14c Weibel J.-M. Blanc A. Pale P. Chem. Rev. 2008; 108: 3149
14d Álvarez-Corral M. Munoz-Dorado M. Rodríguez-García I. Chem. Rev. 2008; 108: 3174
14e Belmont P. Parker E. Eur. J. Org. Chem. 2009; 6075
14f Fang G. Bi X. Chem. Soc. Rev. 2015; 44: 8124
14g Sekine K. Yamada T. Chem. Soc. Rev. 2016; 45

For examples of merging organo- and transition metal-catalysis, see:

15a Ding Q. Wu J. Org. Lett. 2007; 9: 4959
15b Shao Z. Zhang H. Chem. Soc. Rev. 2009; 38: 2745
15c Zhong C. Shi X. Eur. J. Org. Chem. 2010; 2999
15d Arróniz C. Gil-González A. Semak V. Escolano C. Bosch J. Amat M. Eur. J. Org. Chem. 2011; 3755
15e Loh CC. J. Enders D. Chem. Eur. J. 2012; 18: 10212
15f Du Z. Shao Z. Chem. Soc. Rev. 2013; 42: 1337
15g Deng Y. Kumar S. Wang H. Chem. Commun. 2014; 50: 4272

16a Hack D. Loh CC. J. Hartmann JM. Raabe G. Enders D. Chem. Eur. J. 2014; 20: 3917
16b Hack D. Chauhan P. Deckers K. Hermann GN. Mertens L. Raabe G. Enders D. Org. Lett. 2014; 16: 5188
16c Hack D. Chauhan P. Deckers K. Mizutani Y. Raabe G. Enders D. Chem. Commun. 2015; 51: 2266
16d Hack D. Dürr AB. Deckers K. Chauhan P. Seling N. Rübenach L. Mertens L. Raabe G. Schoenebeck F. Enders D. Angew. Chem. Int. Ed. 2016; 53: 1797
16e Kaya U. Chauchan P. Hack D. Deckers K. Puttreddy R. Rissanen K. Enders D. Chem. Commun. 2016; 52: 1669

17a Alemán J. Parra A. Jiang H. Jørgensen KA. Chem. Eur. J. 2011; 17: 6890
17b Storer RI. Aciro C. Jones LH. Chem. Soc. Rev. 2011; 40: 2330
17c Ni X. Li X. Wang Z. Cheng J.-P. Org. Lett. 2014; 16: 1786
17d Chauhan P. Mahajan S. Kaya U. Hack D. Enders D. Adv. Synth. Catal. 2015; 357: 253

18 CCDC 1474771 (5a) and CCDC 1474975 (5d) contain the supplementary crystallographic data for this paper. The data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/getstructures.
19 Yang W. Du D.-M. Adv. Synth. Catal. 2011; 353: 1241

20a Malerich JP. Hagihara K. Rawal VH. J. Am. Chem. Soc. 2008; 130: 14416
20b Zhu Y. Malerich JP. Rawal VH. Angew. Chem. Int. Ed. 2010; 49: 153

Figures